ALBUTEROL SULFATE AND IPRATROPIUM BROMIDE Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Albuterol Sulfate And Ipratropium Bromide, and when can generic versions of Albuterol Sulfate And Ipratropium Bromide launch?
Albuterol Sulfate And Ipratropium Bromide is a drug marketed by Apotex Inc, Cipla, Fosun Pharma, Luoxin Aurovitas, Nephron, Ritedose Corp, Sun Pharm, Teva Pharms, and Watson Labs Teva. and is included in nine NDAs.
The generic ingredient in ALBUTEROL SULFATE AND IPRATROPIUM BROMIDE is albuterol sulfate; ipratropium bromide. There are thirty-eight drug master file entries for this compound. Fifteen suppliers are listed for this compound. Additional details are available on the albuterol sulfate; ipratropium bromide profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Albuterol Sulfate And Ipratropium Bromide
A generic version of ALBUTEROL SULFATE AND IPRATROPIUM BROMIDE was approved as albuterol sulfate; ipratropium bromide by CIPLA on December 31st, 2007.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for ALBUTEROL SULFATE AND IPRATROPIUM BROMIDE?
- What are the global sales for ALBUTEROL SULFATE AND IPRATROPIUM BROMIDE?
- What is Average Wholesale Price for ALBUTEROL SULFATE AND IPRATROPIUM BROMIDE?
Summary for ALBUTEROL SULFATE AND IPRATROPIUM BROMIDE
US Patents: | 0 |
Applicants: | 9 |
NDAs: | 9 |
Finished Product Suppliers / Packagers: | 14 |
Clinical Trials: | 4 |
DailyMed Link: | ALBUTEROL SULFATE AND IPRATROPIUM BROMIDE at DailyMed |
Recent Clinical Trials for ALBUTEROL SULFATE AND IPRATROPIUM BROMIDE
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
James J. Peters Veterans Affairs Medical Center | Phase 2 |
University of Texas Southwestern Medical Center | Phase 4 |
Dey | Phase 3 |
See all ALBUTEROL SULFATE AND IPRATROPIUM BROMIDE clinical trials
Pharmacology for ALBUTEROL SULFATE AND IPRATROPIUM BROMIDE
Drug Class | Anticholinergic beta2-Adrenergic Agonist |
Mechanism of Action | Adrenergic beta2-Agonists Cholinergic Antagonists |